← Eichor
Study identifier: NCT05275218 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Effect of an Intervention to Prevent Acute Kidney Injury Versus Standard Care in High-risk Patients After Major Surgery

Condition: Acute Kidney Injury (Nontraumatic)  ·  Sponsor: University Hospital Muenster

PhaseNA
Planned participants480
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

There is no specific therapy for acute kidney injury. It is presumed that supportive measures improve the care and outcome of patients with acute kidney injury. To investigate whether an implementation of a supportive extended care "bundle" in high-risk patients for persistent acute kidney injury (AKI) can reduce the occurrence of persistent surgical AKI. In order to investigate whether the extended KDIGO bundle can prevent persistent AKI in patients with high chemokine ligand 14 (CCL14) as well as in patients with low CCL14, patients will be randomized with stratification by the CCL-value.

This description comes directly from the study's public registry record.

Talk to the study team

Zarbock, MD  ·  +49-251-8347252  ·  aki@anit.uni-muenster.de

Meersch, MD  ·  aki@anit.uni-muenster.de

Always discuss trial participation with your own doctor first.

Locations (1)

University Hospital Münster; 1Department of Anesthesiology, Intensive Care Medicine and Pain MedicineMünster, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05275218